371 related articles for article (PubMed ID: 15652762)
21. Epitope mapping of antigenic MUC1 peptides to breast cancer antibody fragment B27.29: a heteronuclear NMR study.
Grinstead JS; Schuman JT; Campbell AP
Biochemistry; 2003 Dec; 42(48):14293-305. PubMed ID: 14640698
[TBL] [Abstract][Full Text] [Related]
22. Structural and dynamic consequences of increasing repeats in a MUC1 peptide tumor antigen.
Schuman JT; Grinstead JS; Apostolopoulos V; Campbell AP
Biopolymers; 2005 Feb; 77(2):107-20. PubMed ID: 15635690
[TBL] [Abstract][Full Text] [Related]
23. Recombinant human tumor antigen MUC1 expressed in insect cells: structure and immunogenicity.
Soares M; Hanisch FG; Finn OJ; Ciborowski P
Protein Expr Purif; 2001 Jun; 22(1):92-100. PubMed ID: 11388805
[TBL] [Abstract][Full Text] [Related]
24. Enhancing immunogenicity of a CTL epitope from carcinoembryonic antigen by selective amino acid replacements.
Huarte E; Sarobe P; Lu J; Casares N; Lasarte JJ; Dotor J; Ruiz M; Prieto J; Celis E; Borrás-Cuesta F
Clin Cancer Res; 2002 Jul; 8(7):2336-44. PubMed ID: 12114438
[TBL] [Abstract][Full Text] [Related]
25. MHC-restricted presentation of a single repeat of MUC1 mucin.
Orr MK; Burnside JS; Phillips CA; Philip R; Dombrowski KE; Wright SE
Immunol Invest; 2007; 36(3):271-83. PubMed ID: 17558710
[TBL] [Abstract][Full Text] [Related]
26. Characterization of a new MUC1 monoclonal antibody (VU-2-G7) directed to the glycosylated PDTR sequence of MUC1.
Ryuko K; Schol DJ; Snijdewint FG; von Mensdorff-Pouilly S; Poort-Keesom RJ; Karuntu-Wanamarta YA; Verstraeten RA; Miyazaki K; Kenemans P; Hilgers J
Tumour Biol; 2000; 21(4):197-210. PubMed ID: 10867613
[TBL] [Abstract][Full Text] [Related]
27. Identification and characterization of a WT1 (Wilms Tumor Gene) protein-derived HLA-DRB1*0405-restricted 16-mer helper peptide that promotes the induction and activation of WT1-specific cytotoxic T lymphocytes.
Fujiki F; Oka Y; Tsuboi A; Kawakami M; Kawakatsu M; Nakajima H; Elisseeva OA; Harada Y; Ito K; Li Z; Tatsumi N; Sakaguchi N; Fujioka T; Masuda T; Yasukawa M; Udaka K; Kawase I; Oji Y; Sugiyama H
J Immunother; 2007 Apr; 30(3):282-93. PubMed ID: 17414319
[TBL] [Abstract][Full Text] [Related]
28. Induction of EBV-latent membrane protein 1-specific MHC class II-restricted T-cell responses against natural killer lymphoma cells.
Kobayashi H; Nagato T; Takahara M; Sato K; Kimura S; Aoki N; Azumi M; Tateno M; Harabuchi Y; Celis E
Cancer Res; 2008 Feb; 68(3):901-8. PubMed ID: 18245493
[TBL] [Abstract][Full Text] [Related]
29. Human CTL epitopes prostatic acid phosphatase-3 and six-transmembrane epithelial antigen of prostate-3 as candidates for prostate cancer immunotherapy.
Machlenkin A; Paz A; Bar Haim E; Goldberger O; Finkel E; Tirosh B; Volovitz I; Vadai E; Lugassy G; Cytron S; Lemonnier F; Tzehoval E; Eisenbach L
Cancer Res; 2005 Jul; 65(14):6435-42. PubMed ID: 16024648
[TBL] [Abstract][Full Text] [Related]
30. Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies.
Brossart P; Heinrich KS; Stuhler G; Behnke L; Reichardt VL; Stevanovic S; Muhm A; Rammensee HG; Kanz L; Brugger W
Blood; 1999 Jun; 93(12):4309-17. PubMed ID: 10361129
[TBL] [Abstract][Full Text] [Related]
31. Assessing vaccine potency using TCRmimic antibodies.
Neethling FA; Ramakrishna V; Keler T; Buchli R; Woodburn T; Weidanz JA
Vaccine; 2008 Jun; 26(25):3092-102. PubMed ID: 18353510
[TBL] [Abstract][Full Text] [Related]
32. The epithelial tumor antigen MUC1 is expressed in hematological malignancies and is recognized by MUC1-specific cytotoxic T-lymphocytes.
Brossart P; Schneider A; Dill P; Schammann T; Grünebach F; Wirths S; Kanz L; Bühring HJ; Brugger W
Cancer Res; 2001 Sep; 61(18):6846-50. PubMed ID: 11559560
[TBL] [Abstract][Full Text] [Related]
33. The anti-MUC1 monoclonal antibody BCP8 can be used to isolate and identify putative major histocompatibility complex class I associated amino acid sequences.
Agrawal B; Reddish MA; Christian B; VanHeele A; Tang L; Koganty RR; Longenecker BM
Cancer Res; 1998 Nov; 58(22):5151-6. PubMed ID: 9823326
[TBL] [Abstract][Full Text] [Related]
34. MUC1-specific cytotoxic T lymphocytes eradicate tumors when adoptively transferred in vivo.
Mukherjee P; Ginardi AR; Tinder TL; Sterner CJ; Gendler SJ
Clin Cancer Res; 2001 Mar; 7(3 Suppl):848s-855s. PubMed ID: 11300482
[TBL] [Abstract][Full Text] [Related]
35. Vaccination strategy determines the emergence and dominance of CD8+ T-cell epitopes in a FVB/N rat HER-2/neu mouse model of breast cancer.
Singh R; Paterson Y
Cancer Res; 2006 Aug; 66(15):7748-57. PubMed ID: 16885378
[TBL] [Abstract][Full Text] [Related]
36. Breast carcinoma cell lysate-pulsed dendritic cells cross-prime MUC1-specific CD8+ T cells identified by peptide-MHC-class-I tetramers.
Bohnenkamp HR; Coleman J; Burchell JM; Taylor-Papadimitriou J; Noll T
Cell Immunol; 2004; 231(1-2):112-25. PubMed ID: 15919376
[TBL] [Abstract][Full Text] [Related]
37. MUC1 mucin-mediated regulation of human T cells.
Agrawal B; Longenecker BM
Int Immunol; 2005 Apr; 17(4):391-9. PubMed ID: 15710907
[TBL] [Abstract][Full Text] [Related]
38. Immunogenic HLA-B*0702-restricted epitopes derived from human telomerase reverse transcriptase that elicit antitumor cytotoxic T-cell responses.
Adotévi O; Mollier K; Neuveut C; Cardinaud S; Boulanger E; Mignen B; Fridman WH; Zanetti M; Charneau P; Tartour E; Lemonnier F; Langlade-Demoyen P
Clin Cancer Res; 2006 May; 12(10):3158-67. PubMed ID: 16707616
[TBL] [Abstract][Full Text] [Related]
39. Identification of interleukin-13 receptor alpha2 peptide analogues capable of inducing improved antiglioma CTL responses.
Eguchi J; Hatano M; Nishimura F; Zhu X; Dusak JE; Sato H; Pollack IF; Storkus WJ; Okada H
Cancer Res; 2006 Jun; 66(11):5883-91. PubMed ID: 16740728
[TBL] [Abstract][Full Text] [Related]
40. Synthesis and antibody recognition of synthetic antigens from MUC1.
Bánóczi Z; Mezõ G; Windberg E; Uray K; Majer Z; Hudecz F
J Pept Sci; 2008 May; 14(5):610-6. PubMed ID: 17975847
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
